相关实验视频

Updated: Sep 19, 2025

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

一个用于设计和开发ERK2和多位ERK2/HDAC抑制剂的计算框架

Alen Cebzan¹, Dusan Ruzic¹, Nemanja Djokovic¹

¹Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, Belgrade 11000, Serbia.

Computational biology and chemistry

|June 18, 2025

概括

新的计算方法确定了开发新型ERK2抑制剂的关键结构特征. 这项研究为改善针对MAPK通路的癌症疗法铺平了道路.

科学领域:

在瘤学瘤学.
药用化学医学化学
计算生物学计算生物学

背景情况:

Ras-Raf-MEK-ERK/MAPK通路对于细胞功能至关重要,并且在癌症中经常受到失调.
在这种途径中,ERK2 (细胞外信号调节激酶2) 是一个关键的效应因子,使其成为癌症治疗的目标.
现有的ERK2抑制剂具有局限性,包括安全性问题,疗效和耐药性,需要开发新药.

研究的目的:

使用计算方法识别ERK2抑制活性的关键结构特征.
根据基于碎片的药物设计来设计和评估新的ERK2抑制剂.
探索多位ERK2/HDAC抑制剂在癌症治疗中的潜力.

主要方法:

使用的机器学习-定量结构-活动关系 (ML-QSAR) 和3D-QSAR模型.
采用分子对接来分析化合物-蛋白质相互作用.
执行基于碎片的药物设计和分子动力学模拟以优化.

主要成果:

确定了ERK2抑制的关键结构决定因素.
成功设计和评估了属于pyrimidine-2-pyridone和pyrazolyl-pyrrole类的新ERK2抑制剂.
证明了计算框架在设计多位ERK2/HDAC抑制剂中的有效性.

结论:

开发的计算框架对于设计新型ERK2抑制剂是有效的.
已识别的胺-2-二和醇-醇衍生物显示出作为潜在的癌症治疗药物具有前途.
这项研究为开发先进的多位抑制剂为未来的癌症治疗提供了基础.

关键词:

3D-QSAR 是一个3D-QSAR.接收人接收人基于碎片的药物设计.在HDAC的基础上,HDAC是 ML-QSAR的使用方法分子动力学模拟模型虚拟对接虚拟对接

更多相关视频

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...